Search Results for: CTLA4

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel PPP2R5A protein phosphatase 2 regulatory subunit B'alpha
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Co-stimulation by CD28
  • Co-inhibition by CTLA4
  • Platelet sensitization by LDL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • RHO GTPases Activate Formins
  • RAF activation
  • Negative regulation of MAPK pathway
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
  • PKR-mediated signaling
Novel PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Co-inhibition by CTLA4
  • Co-inhibition by PD-1
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA/IFNB signaling
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • FLT3 Signaling
  • STAT5 Activation
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Co-inhibition by BTLA
  • Dodecyltrimethylammonium
  • Metachondromatosis
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel SKP1 S-phase kinase associated protein 1
  • Activation of NF-kappaB in B cells
  • Prolactin receptor signaling
  • SCF-beta-TrCP mediated degradation of Emi1
  • Vpu mediated degradation of CD4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Regulation of PLK1 Activity at G2/M Transition
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
  • FCERI mediated NF-kB activation
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • NIK-->noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • Regulation of RUNX2 expression and activity
  • Neddylation
  • Interleukin-1 signaling
  • Iron uptake and transport
  • Negative regulation of NOTCH4 signaling
  • Regulation of BACH1 activity
  • Nuclear events stimulated by ALK signaling in cancer
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • Antigen processing: Ubiquitination & Proteasome degradation
  • GSK3B-mediated proteasomal degradation of PD-L1(CD274)
  • Degradation of CRY and PER proteins
  • 1-naphthaleneacetic acid
  • (2S)-2-(1H-indol-3-yl)hexanoic acid
  • (2S)-2-(1H-indol-3-yl)pentanoic acid
  • (2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid
  • Indoleacetic acid
Novel STAT5A signal transducer and activator of transcription 5A
  • Prolactin receptor signaling
  • Nuclear signaling by ERBB4
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signaling by Leptin
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Erythropoietin activates STAT5
  • STAT5 Activation
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Inactivation of CSF3 (G-CSF) signaling
  • Nuclear events stimulated by ALK signaling in cancer
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
Novel STAT5B signal transducer and activator of transcription 5B
  • Prolactin receptor signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signaling by Leptin
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Erythropoietin activates STAT5
  • STAT5 Activation
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Inactivation of CSF3 (G-CSF) signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Dasatinib
  • Growth hormone insensitivity with immunodeficiency
Novel TMEM218 transmembrane protein 218
Novel TXK TXK tyrosine kinase
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Fostamatinib
  • Zanubrutinib
AOX1 aldehyde oxidase 1
  • Vitamin B6 activation to pyridoxal phosphate
  • Cyclobenzaprine
  • Eniluracil
  • Xanthinuria
AP1M1 adaptor related protein complex 1 subunit mu 1
  • Nef mediated downregulation of MHC class I complex cell surface expression
  • MHC class II antigen presentation
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • Neutrophil degranulation
AP2M1 adaptor related protein complex 2 subunit mu 1
  • Nef mediated downregulation of CD28 cell surface expression
  • Nef Mediated CD4 Down-regulation
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Nef Mediated CD8 Down-regulation
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Potential therapeutics for SARS
ATP5MC3 ATP synthase membrane subunit c locus 3
  • Formation of ATP by chemiosmotic coupling
  • Cristae formation
BCS1L BCS1 ubiquinol-cytochrome c reductase complex chaperone
  • Mitochondrial protein import
  • Complex III assembly
  • Bjornstad syndrome
  • Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
CD28 CD28 molecule
  • PIP3 activates AKT signaling
  • Nef mediated downregulation of CD28 cell surface expression
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
CD80 CD80 molecule
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • Interleukin-10 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Abatacept
  • Galiximab
  • Belatacept
CD86 CD86 molecule
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • Interleukin-10 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Antithymocyte immunoglobulin (rabbit)
  • Abatacept
  • Belatacept
  • Bryostatin 1
CDC26 cell division cycle 26
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • Assembly of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
CLK1 CDC like kinase 1
  • Debromohymenialdisine
  • CHGN111
  • ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate
  • Fostamatinib
CTXN3 cortexin 3
DCTD dCMP deaminase
  • Interconversion of nucleotide di- and triphosphates
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Dasatinib
  • Triglyme
  • Fostamatinib
  • Zotiraciclib

Page 2 out of 3 pages